Calypte und die Zeit nach AIDS2004 in Bangkok

...da werden dann wieder ein paar arme schweine reingeritten und das war es dann...

hallo leute: ich finde es zwar gut, dass es gegensätzliche meinungen zur veranlagung in caly gibt, allerding sollte man keinen deswegen mies machen...

ich bleibe für die heutige konferenz positiv eingestellt...

kauf in frankfurt
10:18:04 0,40  14.000  14.000 stk

bis später

Dr. J. Richard George, President and CEO of Calypte stated, "We have used the Adaltis HIV-1/2 peptides in the field trials of our rapid tests in Thailand. Their consistency provides the foundation necessary to achieve the high levels of performance we require for both specificity (false negatives) and sensitivity (false positives). Our field trials have included our blood rapid HIV-1/2 test for which we filed an Investigational Device Exemption Application (IDE) in the US last November, as well as our urine rapid HIV-1/2 test. We have also tested the product in house with other fluids and are pleased with the initial results from both a specificity and sensitivity perspective and are planning to include this additional product in our upcoming field trials later this month."

Dr. George added, "In the community of like sciences, we were encouraged to see that OraSure received FDA approval for their laboratory based rapid oral fluid test for HIV-1. Once our non-laboratory based rapid tests are out of development and into production, we initially plan to distribute them outside the United States. We believe that Calypte's products will soon have world appeal, and after we have introduced our tests internationally, we expect to file for FDA approval for marketing in the US as well. However, our current focus is Sub-Saharan Africa and the "next wave" emerging HIV epidemic countries where the problem is more widespread -- including, China and Russia."

Tony Cataldo, Executive Chairman of Calypte stated, "As Calypte pursues the development of its rapid HIV-1/2 tests, we believe we are now far enough along in our development to begin finalizing the necessary agreements and to start transferring the technology to commercial scale manufacturing. The largest markets in the world are the emerging markets and we believe we are now well positioned to serve those markets. "

Calypte currently has a non-exclusive worldwide distribution agreement with Adaltis Inc. of Montreal, Canada for the distribution of Calypte's serum HIV-1 Western Blot test.

First International Manufacturing Initiative in Thailand

Calypte is preparing for its first foreign manufacturing technology transfer and today also announced that it has signed a Memorandum of Understanding with Thailand-based Pacific Biotech Co., Ltd. to act as Calypte's initial international manufacturer for both its urine and blood rapid tests. Manufacturing will be located at the Pacific Biotech facility in Phetchaboon, Thailand and a formal agreement is expected to be finalized around the middle of April.

Commenting on this arrangement, Dr. George stated, "I have been familiar with the capabilities of Pacific Biotech for several years, and have had past personal experience with them as an ISO 9001 certified contract manufacturer for rapid assays. Our recent audit of their facilities and quality systems tells me that they are an experienced and quality-minded organization that is eminently qualified to manage the manufacturing task ahead of them."

Ninlawan Pichayayothin, President of Pacific Biotech, stated, "The technologies and quality systems involved in this project are very familiar to us. We are confident that we can manufacture the Calypte tests at our facility in both the quality and quantity demanded."

Separately, Calypte confirmed that it continues its focus on China, which the Company believes will be its largest market. Beijing Calypte Biomedical Technology Ltd., the Company's joint venture with Marr Technologies Limited, Calypte's business partner and affiliate of Marr Technologies BV, which owns 28% of Calypte's common stock, has begun negotiations that are expected to lead to a manufacturing joint venture in China that will be controlled by Beijing Calypte. The Company is optimistic that this manufacturing relationship could facilitate a quick regulatory approval process in China.

About Adaltis:

Adaltis Inc. is a privately held company headquartered in Montreal, Canada, and in addition to its Canadian operations, operates its own affiliates in the USA, Italy and Germany, as well as an extensive network of over 60 sub-distributors around the world.

About Pacific Biotech:

Pacific Biotech manufactures high quality diagnostic products to serve the healthcare market world wide on both an OEM basis and under its own brand. It has built a strong reputation for premium quality product and superb customer services for over a decade. Pacific Biotech products and services meet the Thai FDA compliance standards and ISO9001. With the strong support from the Board of Investment and National Science and Technology Development Agency, Pacific Biotech is a model of cooperation between the government and private sectors in promoting the development of a Thai biotechnology industry. Pacific Biotech's products are based on rapid immunochromatographic technologies, and include tests for reproductive hormones, drugs of abuse, and markers of infectious disease.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of in vitro diagnostic tests, primarily for the detection of antibodies to Human Immunodeficiency Virus (HIV), and other sexually transmitted and infectious diseases. Calypte's currently marketed laboratory-based tests include an enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody western blot supplemental test, the only two FDA-approved HIV-1 antibody tests for use on urine samples, as well as an FDA-approved serum HIV-1 antibody western blot supplemental test. Calypte is actively engaged in developing new test products for the rapid detection of HIV and other infectious diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other infectious diseases may make important contributions to public health.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

SOURCE Calypte Biomedical Corporation


040401
PR040403


--------------------------------------------------

diskutiert wird. wer sichere (gähn)-wertschriften kaufen will soll sich mit konservativen bundesanleihen eindecken. wir hoffen aber alle auf das grosse delta beim % & das liegt halt bei zockeraktien drinn, bei anderen papieren hast du nach 20 jahren die teuerung draussen *gg*  

bevor gegen 15:00 Uhr ne goile News kommt, die dann in der Telefonkon. erörtert wird(Wunschdenken). löl

werde bei Burgerking richtig zuschlagen grins

Separately, Calypte confirmed that it continues its focus on China, which the Company believes will be its largest market. Beijing Calypte Biomedical Technology Ltd., the Company's joint venture with Marr Technologies Limited, Calypte's business partner and affiliate of Marr Technologies BV, which owns 28% of Calypte's common stock, has begun negotiations that are expected to lead to a manufacturing joint venture in China that will be controlled by Beijing Calypte. The Company is optimistic that this manufacturing relationship could facilitate a quick regulatory approval process in China.


Pacific Biotech wird der erste große internationale Hersteller werden, da es aber ausländisch ist, wird die Vorbereitungsphase noch andauern.
Dort haben die erstmal Audits durchgeführt ob sie der ISO Norm entsprechen.
Sieht wohl so aus, als wenn Caly da sehr wählerisch bzw. sorgfältig ist.
Noch wurden aber keine Verträge unterschrieben oder ? Sowas kann sich noch hinziehen.

Desweiteren wollen sie sich dann auf den chinesischen Markt konzentrieren, der als größter Markt angesehen wird. Dafür wurden schon die Joint Ventures geschlossen.


Insgesamt eine sehr interessante News, bin ich ja mal gespannt wie sie sich entwickeln.
Wollen wir hoffen das dies keine geschönte/zurechtgebogene news ist. *g*


greetz

n/a  
 15:37:02  
 0.46  
 5'000  

 n/a  
 15:36:46  
 0.465  
 9'000  

 n/a  
 15:36:46  
 0.465  
 50'000  

 n/a  
 15:36:42  
 0.465  
 2'400  

 n/a  
 15:36:15  
 0.465  
 450  

 n/a  
 15:36:04  
 0.465  
 2'400  

 n/a  
 15:35:53  
 0.465  
 2'500  

 n/a  
 15:35:51  
 0.465  
 2'000  

 n/a  
 15:35:32  
 0.465  
 2'400  

 n/a  
 15:35:22  
 0.465  
 2'600  

 n/a  
 15:35:21  
 0.46  
 15'000  

 n/a  
 15:35:08  
 0.465  
 2'400  

 n/a  
 15:34:52  
 0.465  
 20'000  

 n/a  
 15:34:44  
 0.465  
 2'400  

 n/a  
 15:34:40  
 0.465  
 20'000  

 n/a  
 15:34:40  
 0.46  
 350  

 n/a  
 15:34:28  
 0.465  
 20'000  

 n/a  
 15:34:20  
 0.465  
 2'400  

 n/a  
 15:33:52  
 0.465  
 2'400  

 n/a  
 15:33:29  
 0.465  
 2'600  

 n/a  
 15:33:28  
 0.465  
 35'000  

 n/a  
 15:33:26  
 0.465  
 2'600  

 n/a  
 15:33:22  
 0.465  
 2'400  

 n/a  
 15:32:36  
 0.465  
 2'000  

 n/a  
 15:32:36  
 0.46  
 1'000  

 n/a  
 15:32:35  
 0.465  
 2'400  

 n/a  
 15:32:32  
 0.465  
 1'000  

 n/a  
 15:31:57  
 0.465  
 25'000  

 n/a  
 15:30:46  
 0.465  
 1'000  

 n/a  
 15:30:45  
 0.46  
 23'175  

 n/a  
 15:30:32  
 0.465  
 950  

 n/a  
 15:30:16  
 0.465  
 5'000  

 n/a  
 15:30:13  
 0.465  
 300

http://www.ariva.de//board/pneditor/images/em.icon.bigsmile.gif" align=absMiddle border=0